The UK’s National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Lorviqua (lorlatinib) for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults whose disease has progressed after prior treatments.

The institute said that the most likely cost-effectiveness estimates for the treatment are within what it normally considers an acceptable use of NHS resources.

NICE also said Lorviqua meets its criteria to be considered a life-extending treatment.